Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re EGM

13 Aug 2010 16:24

RNS Number : 0819R
Ark Therapeutics Group PLC
13 August 2010
 



ARK THERAPEUTICS GROUP PLC (the "Company")

 

POSTPONEMENT OF EXTRAORDINARY GENERAL MEETING ("EGM")

 

In light of representations made to the Company by a number of shareholders, in part prompted by unavailability over the summer holiday season, the Board has taken the decision to reschedule the EGM from 11.00 a.m. on 19 August 2010 to 12 noon on 6 September 2010. The location of the EGM will not change.

 

This will, in addition, allow the Board to convene and consider in detail the next steps in the implementation of its strategy, informed by its discussions with Iain Ross who has spent the recent weeks working alongside management undertaking a wholesale review of the Group's business and operations. The Board wishes to inform shareholders of the outcome of those deliberations in advance of the EGM and will, therefore, provide a further update as part of its half-yearly report, which is scheduled to be released on 25 August.

 

In accordance with the Articles, the Board shall provide details of the postponed EGM in two UK national newspapers.

 

EGM Deadline and Voting Formalities

 

The current forms of proxy remain valid. The new deadline for the written forms of proxy must be submitted by 12 noon on 2 September 2010. Forms of proxy that have been validly submitted by shareholders to date shall remain valid for the postponed EGM.

 

Save as expressly stated in this document, the contents of the original notice of extraordinary general meeting, including without limitation the business to be conducted at the meeting and the Board's recommendation, shall be unchanged. Words and expressions defined in the original notice for the EGM, shall, unless the context otherwise requires, have the same meaning when read in this document. All other terms and provisions of the Company's original notice for the EGM along with the forms of proxy (all dated 28 July 2010) shall apply. For further details and copies of the relevant documents, please go to www.arktherapeutics.com.

 

A letter has been sent to the Company's shareholders setting out the information above, two copies of which have been sent to the UK Listing Authority Document Viewing Facility and will be available for viewing shortly.

 

 

 

For further information:

 

Ark Therapeutics Group plc

Tel: + 44 (0)20 7388 7722

Martyn Williams, CEO

 

Andrew Christie, Chairman

 

 

 

Financial Dynamics

Tel: +44 (0)20 7831 3113

Ben Atwell

 

Susan Quigley

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDIXDBBGGX
Date   Source Headline
6th Jun 20122:41 pmRNSBlocklisting Interim Review
18th May 201212:02 pmRNSHolding(s) in Company
18th May 201212:01 pmRNSDirector Dealings
18th May 201211:57 amRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
16th May 20127:00 amRNSCompletion of Phase 1 Study
2nd May 20127:00 amRNSGrant and Patent Update
25th Apr 20127:00 amRNSRegulatory Approval of Manufacturing Suite
17th Apr 20122:36 pmRNSDirector/PDMR Shareholding
10th Apr 20127:00 amRNSNew Board Appointment
2nd Apr 20123:25 pmRNSAnnual Information Update
26th Mar 20127:00 amRNSChange of Broker Name
15th Mar 20124:09 pmRNSDirector/PDMR Shareholding
13th Mar 20124:16 pmRNSBoard Changes
12th Mar 20127:00 amRNSFinal Results
23rd Feb 20124:29 pmRNSHolding(s) in Company
9th Feb 201211:10 amRNSNotice of Results
8th Feb 20127:00 amRNSUS patent for Neuropilin-1 receptor
4th Jan 20127:00 amRNSManufacturing Update
7th Dec 201111:48 amRNSDirector/PDMR Shareholding
5th Dec 20112:35 pmRNSBlocklisting Interim Review
9th Nov 20117:00 amRNSInterim Management Statement
3rd Nov 20117:00 amRNSManufacturing agreement
16th Sep 20114:41 pmRNSSecond Price Monitoring Extn
16th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20117:00 amRNSRe Agreement
24th Aug 20115:29 pmRNSHalf Yearly Report on National Storage Mechanism
24th Aug 20117:00 amRNSHalf Yearly Report - Part 2
24th Aug 20117:00 amRNSHalf Yearly Report - Part 1
1st Aug 20114:31 pmRNSHolding(s) in Company
29th Jul 20114:40 pmRNSSecond Price Monitoring Extn
29th Jul 20114:35 pmRNSPrice Monitoring Extension
25th Jul 20114:40 pmRNSSecond Price Monitoring Extn
25th Jul 20114:35 pmRNSPrice Monitoring Extension
18th Jul 20113:10 pmRNSHolding(s) in Company
14th Jul 20117:00 amRNSWins ?5.3 million EU Framework Programme 7 Grant
6th Jul 20117:00 amRNSArk receives Finnish Grants
4th Jul 20117:00 amRNSGrant of US patents and milestone payments
13th Jun 20114:40 pmRNSSecond Price Monitoring Extn
13th Jun 20114:35 pmRNSPrice Monitoring Extension
3rd Jun 201111:57 amRNSBlocklisting Interim Review
17th May 20117:00 amRNSInterim Management Statement
9th May 20113:28 pmRNSAGM Results
31st Mar 20111:43 pmRNSAnnual Information Update
30th Mar 20111:08 pmRNSDirector/PDMR Shareholding
24th Mar 20113:40 pmRNSAnnual Financial Report
9th Mar 20117:00 amRNSFinal Results
3rd Mar 20117:00 amRNSAppointment of CFO
2nd Mar 20117:00 amRNSDisposal
28th Feb 201111:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.